Why Is SELLAS LIFE SCIENCES (SLS) Stock Up Today?

SLS stock is up 12.09% at $11.22 in today’s session driven by nearly $6 million in new institutional buying. Opus Capital increased its stake by 11.3% to hold 385,604 shares valued at approximately $5.69 million. The move comes after a week of negative price action that saw the stock fall 18.6% over eight sessions.

What Happened

Fresh institutional investment in SELLAS Life Sciences is the primary catalyst for the stock’s sharp intraday rally. Opus Capital’s recent purchase of additional shares signals a growing institutional interest in the biopharmaceutical company despite its unprofitable status and high beta of 2.43. This follows a week in which SLS shares declined from $12.20 to $9.94, testing resistance levels and drawing attention from market participants. The firm’s market cap currently stands at $2.0 billion, with a trailing twelve-month earnings per share of -0.23.

What The Data Shows

The stock’s 52-week range of $1.39 to $15.88 suggests it remains within a broader trading pattern. The recent 18.6% drop over eight sessions contrasts with today’s strong reversal. While retail sentiment remains bearish, institutional accumulation points to a shift in positioning. SLS is also operating in a volatile environment, with a beta significantly above the market average.

What To Watch

Investors should monitor the company’s upcoming earnings report if scheduled, or watch for additional institutional activity that could influence the stock’s near-term direction. Coverage breadth is currently limited to one story in the past 36 hours.